# 3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol

> **NCT05458622** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **University Hospital, Brest** · enrollment: 25 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)

## Interventions

- **BIOLOGICAL:** Blood sample
- **BIOLOGICAL:** Urine sample
- **BIOLOGICAL:** Saliva sample
- **BIOLOGICAL:** Stood sample
- **PROCEDURE:** Tissue sample

## Key facts

- **NCT ID:** NCT05458622
- **Lead sponsor:** University Hospital, Brest
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-29
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05458622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05458622, "3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05458622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*